Brief: Viking Therapeutics Announces Positive Topline Results From Maintenance Study Of Glp-1/Gip Agonist Vk2735 Demonstrating The Promise Of Multiple Maintenance Dosing Regimens
22/09/2026 12:09
BRIEF-Viking Therapeutics Announces Positive Topline Results From Maintenance Study Of Glp-1/Gip Agonist Vk2735 Demonstrating The Promise Of Multiple Maintenance Dosing Regimens Sept 22 (Reuters) - Viking Therapeutics, Inc. VKTX.O:
VIKING THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM MAINTENANCE STUDY OF GLP-1/GIP AGONIST VK2735 DEMONSTRATING THE PROMISE OF MULTIPLE MAINTENANCE DOSING REGIMENS
VIKING THERAPEUTICS, - REPORTS 22% PLACEBO-ADJUSTED WEIGHT LOSS AT WEEK 33 WITH VK2735 17.5 MG WEEKLY DOSING
VIKING THERAPEUTICS, - UP TO 97% WEIGHT LOSS MAINTAINED WITH EVERY-OTHER-WEEK DOSING FOR THREE MONTHS
VIKING THERAPEUTICS, - UP TO 90% WEIGHT LOSS MAINTAINED WITH MONTHLY DOSING FOR THREE MONTHS
VIKING THERAPEUTICS, - MAINTENANCE DOSING SHOWS GI ADVERSE EVENT RATES SIMILAR TO PLACEBO
Source text: ID:nPn7KpWwca
Further company coverage: VKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viking Therapeutics
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry